The exciting part here is this is validation of the tech, with many other potential use cases. Pre-eclampsia market opportunity estimated at $1.88bil. Further opportunities identified;
Remote Patient Monitoring - $175 bil
Health Wearables - $104bil
Decentralized Clinical Trials - $14bil
Hypertension and arterial healthmonitoring - $1.18bil
Monitoring and management ofheart failure patients - $3.32bil
A Dementia Therapeutic Program - $4bil
The blue sky potential here is excellent for a company valued at ~$22mil, with strong tech validation on the cusp of commercialising their product which has been years of development.
https://hotcopper.com.au/threads/ann-cdx-january-2024-webinar-presentation.7806625/
I'll settle for first sales in December, looking forward to an update in the quarterly. Nice to see Scarlett a bit more chipper with a slight bump in share price, can only imagine the excitement in future!
Add to My Watchlist
What is My Watchlist?
